Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Telix Pharmaceuticals (TLX AU): Achieves 2025 Guidance; Geography and Portfolio Expansion on Card

Telix Pharmaceuticals (TLX AU): Strong Operating Performance in 3Q25; 2025 Guidance Raise

Telix Pharmaceuticals (TLX AU): Shares Are Bouncing off Lows; Driving Forces Behind and What’s Next

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/telix-pharmaceuticals-ltd" target="_blank" data-smartkarma-citation="entities:26052:1" rel="noopener">Telix Pharmaceuticals (TLX AU)</a> reported 1H26 revenue of $477M, up 22% YoY, driven by Precision Medicine, tracking in line with the upper end of full year guidance of $950–970M.</li>
<li>Pixclara, an investigational PET imaging agent for the characterization of recurrent or progressive glioma (brain cancer), has been granted a PDUFA goal date by the FDA of September 11, 2026.</li>
<li>With two‑product PSMA imaging strategy (Illuccix and Gozellix) differentiated clinical positioning, and expanding commercial presence globally, Telix is well-positioned for continued growth.</li>
</ul>



Telix Pharmaceuticals (TLX AU) reported 1H26 revenue of $477M, up 22% YoY, driven by Precision Medicine, tracking in line with the upper end of full year guidance of $950–970M.
Pixclara, an investigational PET imaging agent for the characterization of recurrent or progressive glioma (brain cancer), has been granted a PDUFA goal date by the FDA of September 11, 2026.
With two‑product PSMA imaging strategy (Illuccix and Gozellix) differentiated clinical positioning, and expanding commercial presence globally, Telix is well-positioned for continued growth.


Telix Pharmaceuticals (TLX AU): Stellar H1 Financial Performance; Eye on Upcoming Approval